CAS 127-07-1 MFCD00007943-Hydroxyurea 羟基脲 TAO{mole}

Hydroxyurea 羟基脲

CAS 127-07-1 MFCD00007943

化学结构图

SMILES: NC(=O)NO

化学属性

Mol. Formula	C
Mol. Weight	76
Density	1.457
Melting Point	135
Solubility	可溶
TSCA	No
Appearance	powder 白色针状结晶。熔点70-72℃（分解）或141℃分解。易溶于水和热乙醇，微溶于冷乙醇，不溶于乙醚、苯。遇水或热不稳定。无臭，无味。

别名和识别编码

Chemical Name	Hydroxyurea
CAS Number	127-07-1
Synonym	######## Biosupressin Carbamohydroxamic acid Carbamoylhydroxylamine HU HYDROXYCARBAMIDE Hydrea Hydreia Hydroxycarbamide Hydroxycarbamine Hydroxylamine, N-carbamoyl- Hydura Litalir N-Carbamoylhydroxylamine N-HYDROXYUREA N-Hydroxyurea N-羟基脲 NSC 32065 Oxyurea SQ 1089 carbamohydroxamicacid hu hydrea hydroxy-ure hydroxycarbamine hydroxylurea hydroxyurea(d4) hydura {} {} {} {} {uni_hamburg} 氨基甲酰基羟胺氨甲酰羟基胺羟基尿素羟基尿素,氨基甲酰基羟胺羟基脲羥[基]脲
EC Number	204-821-7
Beilstein Registry Number	1741548
MDL Number	MFCD00007943
PubChem Substance ID	3657
Merck Number	4848
Alfabeta Name	HYDROXYUREA
Chemical Name Translation	羟基脲
Reaxys-RN	1741548
Wiswesser Line Notation	ZVMQ
LabNetwork Molecule ID	LN00184085
InChI	InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)

信息真实价格透明资金保障专业采购外包团队在线服务

品牌质保精细包装现货库存一流品牌服务

产品应用

抗肿瘤。靠形成游离的一氧化氮，结合到酶活性部位的酪氨酸而使核苷还原酶失活。这阻碍了脱氧核苷酸的合成
医药上用于慢性粒细胞白血病的治疗，也用于治疗转移性卵巢癌、头颈部原发性鳞癌、顽固性牛皮癣等。该品为抗肿瘤药物。

安全信息

Signal word Danger Warning

GHS Symbol

WGK Germany3

Safety Statements

S20 When using do not eat or drink 使用时，不得进食，饮水；
S26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice 眼睛接触后，立即用大量水冲洗并征求医生意见；
S36 Wear suitable protective clothing 穿戴适当的防护服；
S36/37 Wear suitable protective clothing and gloves 穿戴适当的防护服和手套；
S36/37/39 Wear suitable protective clothing, gloves and eye/face protection 穿戴适当的防护服、手套和眼睛/面保护；
S45 In case of accident or if you feel unwell seek medical advice immediately (show the label where possible) 发生事故时或感觉不适时，立即求医（可能时出示标签）；
S53 Avoid exposure - obtain special instructions before use 避免接触，使用前获得特别指示说明；

Risk Statements

R36/37/38 Irritating to eyes, respiratory system and skin 对眼睛、呼吸系统和皮肤有刺激性
R46 May cause inheritable genetic damage 可能引起遗传基因损害
R61 May cause harm to the unborn child 可能对未出生的婴儿导致伤害
R63 Possible risk of harm to the unborn child 可能危害未出生婴儿

Precautionary statements

P201 Obtain special instructions before use. 使用前获取专门指示。
P202 Do not handle until all safety precautions have been read and understood. 已阅读并理解所有的安全预防措施之前，切勿操作。
P280 Wear protective gloves/protective clothing/eye protection/face protection. 戴防护手套/防护服/眼睛的保护物/面部保护物。
P281 Use personal protective equipment as required. 使用所需的个人防护装备。
P308+P313
P405 Store locked up. 上锁保管。
P501 Dispose of contents/container to..… 处理内容物/容器.....

Hazard statements

H361 Suspected of damaging fertility or the unborn child 怀疑对生育能力或未出生婴儿造成伤害
H340 May cause genetic defects 可能导致遗传性缺陷

Personal Protective Equipment Eyeshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges

RTECSYT4900000

Hazard Codes 6.1 T

Warnings IRRITANT

Packing GroupIII

UN Number 2811

Storage condition 2-8°C 储存温度2-8°C

Hazard Class6.1

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Subcutaneous
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 500 mg/kg
TOXIC EFFECTS :
   Tumorigenic - equivocal tumorigenic agent by RTECS criteria
   Lungs, Thorax, or Respiration - tumors
   Skin and Appendages - tumors
REFERENCE :
   IJCAAR Indian Journal of Cancer.  (Indian Cancer Soc., Parel, Bombay, 400
   012, India)  V.1-    1963-  Volume(issue)/page/year: 10,26,1973

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 2500 mg/kg/7W-I
TOXIC EFFECTS :
   Tumorigenic - equivocal tumorigenic agent by RTECS criteria
   Endocrine - tumors
   Endocrine - adrenal cortex tumors
REFERENCE :
   CANCAR Cancer (Philadelphia).  (Lippincott/Harper, Journal Fulfillment
   Dept., 2350 Virginia Ave., Hagerstown, MD 21740)  V.1-    1948-
   Volume(issue)/page/year: 40,1935,1977

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 9750 mg/kg/26W-I
TOXIC EFFECTS :
   Tumorigenic - equivocal tumorigenic agent by RTECS criteria
   Blood - leukemia
   Blood - lymphoma, including Hodgkin's disease
REFERENCE :
   CANCAR Cancer (Philadelphia).  (Lippincott/Harper, Journal Fulfillment
   Dept., 2350 Virginia Ave., Hagerstown, MD 21740)  V.1-    1948-
   Volume(issue)/page/year: 40,1935,1977

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intravenous
SPECIES OBSERVED        : Mammal - dog
DOSE/DURATION           : >1 gm/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   IYKEDH Iyakuhin Kenkyu.  Study of Medical Supplies.  (Nippon Koteisho
   Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan)  V.1- 1970- 
   Volume(issue)/page/year: 23,682,1992

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intravenous
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 4730 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   IYKEDH Iyakuhin Kenkyu.  Study of Medical Supplies.  (Nippon Koteisho
   Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan)  V.1- 1970- 
   Volume(issue)/page/year: 23,682,1992

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intravenous
SPECIES OBSERVED        : Human
DOSE/DURATION           : 86 mg/kg
TOXIC EFFECTS :
   Gastrointestinal - nausea or vomiting
   Blood - other changes
REFERENCE :
   CCROBU Cancer Chemotherapy Reports, Part 1.  (Washington, DC)  V.52(6)-59,
   1968-75.  For publisher information, see CTRRDO.  Volume(issue)/page/year:
   57,369,1973

TYPE OF TEST            : LD10 - Lethal Dose
ROUTE OF EXPOSURE       : Subcutaneous
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 2400 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   EJCAAH European Journal of Cancer.  (Oxford, UK)  V.1-17(6), 1965-1981. For
   publisher information, see EJCODS.  Volume(issue)/page/year: 10,667,1974

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSER

TYPE OF TEST            : Mutation in microorganisms
TEST SYSTEM             : Bacteria - Salmonella typhimurium
DOSE/DURATION           : 1 mg/plate
REFERENCE :
   ENMUDM Environmental Mutagenesis.  (New York, NY)  V.1-9, 1979-87.  For
   publisher informa

TYPE OF TEST            : Mutation test systems - not otherwise specified
TEST SYSTEM             : Bacteria - Escherichia coli
DOSE/DURATION           : 1 mmol/L
REFERENCE :
   MUREAV Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE
   Amsterdam, Netherlands) V.1-    1964-  Volume(issue)/page/year: 192,105,1987

TYPE OF TEST            : Mutation test systems - not otherwise specified
TEST SYSTEM             : Human Lymphocyte
DOSE/DURATION           : 80 mg/L
REFERENCE :
   BJCAAI British Journal of Cancer.  (Macmillan Press Ltd., Houndmills,
   Basingstoke, Hants. RG21 2XS, UK)  V.1-    1947-  Volume(issue)/page/year:
   23,337,1969

TYPE OF TEST            : DNA inhibition
TEST SYSTEM             : Microorganism - not otherwise specified
DOSE/DURATION           : 75 mmol/L
REFERENCE :
   GENRA8 Genetical Research.  (Cambridge Univ. Press, 32 E. 57th St., New
   York, NY 10022) V.1-    1960-  Volume(issue)/page/year: 31,215,1978

TYPE OF TEST            : DNA inhibition
TEST SYSTEM             : Human Cells - not otherwise specified
DOSE/DURATION           : 50 mg/L
REFERENCE :
   26QZAP "Advances in Antimicrobial and Antineoplastic Chemotherapy, Progress
   in Research and Clinical Application, 7th Proceedings of the International
   Congress of Chemotherapy, Prague, 1971," Hejzlar, M., et al., eds., 3 vols.,
   Prague, Czechoslovakia, Univ. Press, 1972  Volume(issue)/page/year:
   2,395,1972

{hazard_com

TYPE OF TEST            : DNA inhibition
ROUTE OF EXPOSURE       : Parenteral
TEST SYSTEM             : Rodent - rat
DOSE/DURATION           : 1500 mg/kg/3D (Continuous)
REFERENCE

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Unreported
SPECIES OBSERVED        : Rodent - mouse
DOSE                    : 500 mg/kg
SEX/DURATION            : female 10 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Effects on Embryo or Fetus - cytological changes (including
   somatic cell genetic material)
REFERENCE :
   TJADAB Teratology, The International Journal of Abnormal Development. (Alan
   R. Liss, Inc., 41 E. 11th St., New York, NY 10003)  V.1-    1968-
   Volume(issue)/page/year: 29(3),17A,1984

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Mammal - dog
DOSE                    : 450 mg/kg
SEX/DURATION            : female 20-22 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Specific Developmental Abnormalities - musculoskeletal system
   Reproductive - Specific Developmental Abnormalities - gastrointestinal
   system
   Reproductive - Specific Developmental Abnormalities - homeostasis
REFERENCE :
   28QFAD "Laboratory Animals in Drug Testing, Symposium of the 5th
   International Committee on Laboratory Animals, Hanover, 1972," Speigel, A.
   ed., Stuttgart, Fed. Rep. Ger., Gustav Fischer Verlag, 1973
   Volume(issue)/page/year: -,233,1973

{h

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intravenous
SPECIES OBSERVED        : Rodent - hamster
DOSE                    : 400 mg/kg
SEX/DURATION            : female 8 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Effects on Embryo or Fetus - fetal death
   Reproductive - Specific Developmental Abnormalities - cardiovascular
   (circulatory) system
REFERENCE :
   ARPAAQ Archives of Pathology.  (Chicago, IL)  V.5(3)-50(3), 1928-50;
   V.70-99, 1960-75.  For publisher information, see APLMAS.
   Volume(issue)/page/year: 81,174,1966

{hazard_

其他信息

Sigma Aldrich:127-07-1(sigmaaldrich)
下游产品:利谷隆
不良反应、禁忌和药物影响:骨髓抑制为剂量限制性毒性，羟基脲可致白细胞和血小板减少，停药后1～2周可恢复；有时出现胃肠道反应，皮疹、排尿困难、损伤肾小管、有致睾丸萎缩和致畸胎的报道；偶有中枢神经系统症状和脱发，有引起药物性发热的报道，重复给药时可再现。有过敏史、血小板低于50×109/L、水痘、带状疱疹及各种严重感染者禁用。妊娠、哺乳期妇女禁用。羟基脲可减少5-氟尿嘧啶转变为活性代谢物，同用应慎重；用羟基脲时慎用巴比妥类、安定类、麻醉药等；与别嘌呤醇、秋水仙碱、丙磺舒等合用治疗痛风时，须调整上述药物剂量。用药期间避免接种病毒疫苗，停药3个月至1年才可接种疫苗。服用羟基脲片时应适当增加液体的摄入量，以增加尿量及尿酸的排泄。定期监测白细胞、血
用途一:该品为抗肿瘤药物。
方法一:由氨甲酸乙酯与盐酸羟胺反应而得。将氢氧化钠溶液冷至20-25℃。搅拌下交替加入氨甲酸乙酯及盐酸羟胺，在25-28℃反应16h。用盐酸中和至pH为6.5-7，控制温度不超过25℃。然后减压浓缩，趁热过滤，滤夜冷却至0℃以下析出结晶。过滤，结晶用冰水洗涤，干燥，得羟基脲粗品。收率约65%。经精制可得医药级羟基脲。
用途二:用于慢性粒细胞白血病的治疗，也用于治疗转移性卵巢癌、头颈部原发性鳞癌、顽固性牛皮癣等。该品为抗肿瘤药物。
TCI Shanghai:羟基尿 Hydroxyurea,>;95.0%(N)(127-07-1)
MSDS 信息:Hydroxyurea(127-07-1).msds
药物作用及临床应用:羟基脲是治疗慢性粒细胞白血病的抗癌药，早在20年代就观察到羟基脲使兔产生与恶性贫血相似的巨成红细胞血象，并抑制白细胞生成。1963年发现它对L1210小鼠白血病的抑制作用。羟基脲能够诱导细菌产生一种对自身有毒性的分子从而达到杀死细菌的目的。羟基脲又称羟基脲素、羟脲、氨甲酰羟基脲，是一种核苷二磷酸还原酶抑制剂，可阻止核苷酸还原为脱氧核苷酸，干扰嘌呤及嘧啶碱基生物合成，选择性阻碍DNA合成，部分抑制核糖核酸转化为脱氧核糖核苷酸。对RNA及蛋白质合成无阻断作用。羟基脲为周期特异性药物，对S期细胞敏感，能诱导慢性
用法与用量:成人常用量： ①慢性粒细胞白血病，一般开始剂量为每日按体重20～30mg/kg，1次或分2次口服，当白细胞下降至10×109/L以下时，减量至约为每日20mg/kg，口服维持或改间歇服用。 ②头颈癌、卵巢癌，剂量为每次按体重60～80mg/kg，或按体表面积2000～3000mg/m2，每3日口服1次，单独服用或与放疗合用。
MOL 文件:127-07-1.mol
羟基脲价格(试剂级):更新日期产品编号产品名称包装价格 2014/06/02 H0310 羟基脲 Hydroxyurea 25G 2570元 2014/06/02 H0310 羟基脲 Hydroxyurea 5G 702元 2010/06/21 151681000 羟基脲 Hydroxyurea 98% 100 GR 7932元
Acros Organics:羟基脲 Hydroxyurea, 98%(127-07-1)
易溶于水和热乙醇，微溶于冷乙醇，不溶于乙醚；苯。遇水或热不稳定。无臭，无味。
不良反应、禁忌和药物影响:骨髓抑制为剂量限制性毒性，羟基脲可致白细胞和血小板减少，停药后1～2周可恢复；有时出现胃肠道反应，皮疹、排尿困难、损伤肾小管、有致睾丸萎缩和致畸胎的报道；偶有中枢神经系统症状和脱发，有引起药物性发热的报道，重复给药时可再现。有过敏史、血小板低于50×109/L、水痘、带状疱疹及各种严重感染者禁用。妊娠、哺乳期妇女禁用。羟基脲可减少5-氟尿嘧啶转变为活性代谢物，同用应慎重；用羟基脲时慎用巴比妥类、安定类、麻醉药等；与别嘌呤醇、秋水仙碱、丙磺舒等合用治疗痛风时，须调整上述药物剂量。用药期间避免接种病毒疫苗，停药3个月至1年才可接种疫苗。服用羟基脲片时应适当增加液体的摄入量，以增加尿量及尿酸的排泄。定期监测白细胞、血小板、血中尿素氮、尿酸及肌苷浓度。
Alfa Aesar: